VEGFA and malignant colon neoplasm: The AVANT trial aimed to investigate whether combining bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, with standard chemotherapy would improve survival among colon cancer patients30,33.